Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Kubitza, Dagmar; Becka, Michael; Mueck, Wolfgang; Halabi, Atef; Maatouk, Haidar; Klause, Norbert; Lufft, Volkmar; D. Wand, Dominic; Philipp, Thomas; Bruck, Heike

doi:10.1111/j.1365-2125.2010.03753.x

Public

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Published in British Journal of Clinical Pharmacology • Jul 15, 2010

Authors:

Dagmar Kubitza

Michael Becka

Wolfgang Mueck

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Prior to the commencement of this study, it was already known that rivaroxaban is partially cleared via the kidneys and an influence of renal insufficiency on rivaroxaban pharmacokinetics and exposure was anticipated. WHAT THIS STUDY ADDS • As many patients...

Subject

Rivaroxaban

Medicine

Pharmacokinetics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!